Abstract
Migraine is characterized by attacks of intense pulsatile and throbbing headache, typically unilateral in nature with or without aura. Migraine affects a substantial fraction (10-20 %) of the world population (more women than men). With regard to the pathophysiology of migraine, several theories have been proposed; the major three are vascular (due to cerebral vasodilatation), neurological (abnormal neurological firing) and neurogenic dural inflammation (release of inflammatory neuropeptides). The drugs used to treat migraine can be divided into two groups: agents that abolish the acute migraine headache and agents aimed at prevention. The acutely acting antimigraine agents (5-HT1B/1D receptor agonists) stimulated research interest in the field of migraine. Currently prophylactic treatments for migraine include calcium channel blockers, 5-HT2 receptor antagonists, beta-adrenoceptor blockers and γ-amino butyric acid (GABA) agonists. Unfortunately, many of these treatments are non-specific and not always effective. Despite progress, the complex etiology of migraine requires further research, the condition often remains undiagnosed and available therapies are underused. In this review, the evidence that linked the different theories of migraine with its pathophysiology is considered. Furthermore, the present therapeutic targets and future approaches for the acute and prophylactic treatment of migraine are critically evaluated.
Keywords: Migraine, headache, serotonin, vasodilatation
Current Vascular Pharmacology
Title: Migraine: Current Therapeutic Targets and Future Avenues
Volume: 4 Issue: 2
Author(s): D. K. Arulmozhi, A. Veeranjaneyulu and S. L. Bodhankar
Affiliation:
Keywords: Migraine, headache, serotonin, vasodilatation
Abstract: Migraine is characterized by attacks of intense pulsatile and throbbing headache, typically unilateral in nature with or without aura. Migraine affects a substantial fraction (10-20 %) of the world population (more women than men). With regard to the pathophysiology of migraine, several theories have been proposed; the major three are vascular (due to cerebral vasodilatation), neurological (abnormal neurological firing) and neurogenic dural inflammation (release of inflammatory neuropeptides). The drugs used to treat migraine can be divided into two groups: agents that abolish the acute migraine headache and agents aimed at prevention. The acutely acting antimigraine agents (5-HT1B/1D receptor agonists) stimulated research interest in the field of migraine. Currently prophylactic treatments for migraine include calcium channel blockers, 5-HT2 receptor antagonists, beta-adrenoceptor blockers and γ-amino butyric acid (GABA) agonists. Unfortunately, many of these treatments are non-specific and not always effective. Despite progress, the complex etiology of migraine requires further research, the condition often remains undiagnosed and available therapies are underused. In this review, the evidence that linked the different theories of migraine with its pathophysiology is considered. Furthermore, the present therapeutic targets and future approaches for the acute and prophylactic treatment of migraine are critically evaluated.
Export Options
About this article
Cite this article as:
Arulmozhi K. D., Veeranjaneyulu A. and Bodhankar L. S., Migraine: Current Therapeutic Targets and Future Avenues, Current Vascular Pharmacology 2006; 4 (2) . https://dx.doi.org/10.2174/157016106776359853
DOI https://dx.doi.org/10.2174/157016106776359853 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews Anti-Oxidative Stress and Beyond: Multiple Functions of the Protein Glutathionylation
Protein & Peptide Letters Medical Treatment of Malignancy-Associated Hypercalcemia
Current Medicinal Chemistry Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development)
Current Pharmaceutical Design Editorial (Thematic Issue: Immunologic Mechanisms in Neurological Diseases)
Current Immunology Reviews (Discontinued) Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment
Current Drug Safety A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Off-Label Use of Medications for Treatment of Benzodiazepine Use Disorder
Current Pharmaceutical Design Locked Nucleic Acid Holds Promise in the Treatment of Cancer
Current Pharmaceutical Design CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes
Current Drug Targets Integrating Autism Spectrum Disorder Pathophysiology: Mitochondria, Vitamin A, CD38, Oxytocin, Serotonin and Melatonergic Alterations in the Placenta and Gut
Current Pharmaceutical Design Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Molecular Mechanisms of Curcumin in Neuroinflammatory Disorders: A Mini Review of Current Evidences
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Executive Functioning in PTSD and its Treatment
Current Psychiatry Reviews Neurosteroids and Sporadic Alzheimers Disease
Current Alzheimer Research New Strategies and Patent Therapeutics in EBV-Associated Diseases
Mini-Reviews in Medicinal Chemistry Rational Basis for Nutraceuticals in the Treatment of Glaucoma
Current Neuropharmacology Association Study of 10 Candidate Genes with Sporadic Alzheimers Disease in a Spanish Population
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Release Characteristics In Vitro and In Vivo of In Situ Gels for a Novel Peptide Compared with Low-Molecular-Weight Hydrophilic Drug
Current Drug Delivery